Glenmark Pharmaceuticals has launched a generic version of Epinephrine injection multiple-dose vial in the US, gaining 180 days of CGT exclusivity. The injection treats hypotension from septic shock and allergic reactions. Glenmark's product, bioequivalent to BPI Labs' reference drug, adds to their institutional portfolio and achieved annual sales close to USD 42.7 million as of December 2024.